Clinical effect of Linagliptin on treating type 2 diabetic patients with early diabetic kidney disease

Abstract

Objective To assess the clinical effect of Linagliptin on treating type 2 diabetic patients with early diabetic kidney disease. Methods Fifty cases type 2 diabetes patients with early diabetic kidney disease were selected and randomly divided into two groups.All patients carried out diabetes education, strict diet therapy, and proper exercise.Twenty-six cases patients were enrolled in Linagliptin group, oral Linagliptin 5 mg, 1 times/d.Twenty-four cases patients were enrolled in Gliclazide group, oral Gliclazide 30 mg, 1 times/d, and monitored the blood sugar to adjust drug dosage, the maximum dose of 60 mg, 1 times/d.The observation time of both groups was six months.The glycosylated hemoglobin(HbA1c) and urinary albumin-to-creatinine ratio(UACR) of two groups were compared before and after treatment. Results The level of HbA1c in Linagliptin group after treatment was lower than before treatment, the difference was significant((7.39±0.37)% vs.(8.30±0.48)%, t=14.232, P<0.001). The level of HbA1c in Gliclazide group after treatment was lower than before treatment, the difference was significant((7.45±0.41)% vs.(8.38±0.49)%, t=23.146, P<0.001). There was no significant difference on the level of HbA1c between the two groups after treatment(t=-0.517, P=0.608). The level of UACR in Linagliptin group after treatment was lower than before treatment, the difference was significant((83.64±37.44) mg/g vs.(109.56±53.36) mg/g, t=4.632, P<0.001). The level of UACR in Gliclazide group after treatment was lower than before treatment, the difference was significant((93.58±47.17) mg/g vs.(103.77±48.80) mg/g, t=2.909, P=0.008). There was significant difference on the level of UACR between the two groups after treatment(t=-2.172, P=0.035). Conclusion Linagliptin is a kind of effective and safe regent, can be used in patients with type 2 diabetes and early diabetic kidney disease. Key words: Linagliptin; Type 2 diabetes; Diabetic kidney disease; Urinary albumin-to-creatinine ratio